Trump Administration Budget Blueprint Comes With Major Cuts to Health and Science
Greater Transparency at FDA Would Bring More Biosimilars to Market, Experts Say
Dr Scott Gottlieb, Trump's FDA Pick, a Consistent Supporter of Biosimilar Innovation
Mylan's Settlement With Genentech and Roche Opens US Market for Trastuzumab Biosimilar
European Industry Groups Urge Caution on Biosimilar Switching
Merck KGaA Close to Selling Biosimilars Division to Undisclosed Buyer
Amgen Lawsuit Against Coherus Alleges Misappropriation of Neulasta Trade Secrets
Siliq Approved Without a Suffix
Sandoz Releases Efficacy Data for Its Humira Biosimilar
New Delhi High Court Allows Marketing of Biocon-Mylan Biosimilar of Trastuzumab
FDA's Director of Drug Evaluation Urges Congress to Pass the BsUFA Reauthorization
US and EU Agree on Mutual Recognition of Drug Manufacturing Inspections
Bioequivalence Endpoints Successfully Met for Humira Biosimilar, Coherus Announces
Targeted Regenerative Meds Hold Promise for RA Patients Resistant to anti-TNF Agents
Diabetes Drugs Could Be Next Frontier of Biosimilar Development
Will the Biosimilars Bubble Burst Even Before It Expands?
New Mexico Senate Passes Bill for Biosimilar Substitution
FDA Should Forge Ahead on Biosimilar Drug Reviews: A Rheumatologist's Opinion
Amgen-Harvard Pilgrim Enter Outcomes-Based Contract for Enbrel
Truxima Receives Approval in EU for Autoimmune, Oncology Indications
Will US Follow UK on Managed Biosimilar Switching of IBD Patients on Infliximab?
Biosimilars Council Wants Elimination of 6-Month Exclusivity for Biologics
How Will the Genentech-Amgen Feud Bear Down on Biosimilar Development?
FDA Accepts Mylan-Biocon Pegfilgrastim Biosimilar Application
AbbVie, Novartis Unhappy With FDA Guidance on Naming Biologics and Biosimilars
Herceptin, Rituxan Biosimilars Might Soon Reach Oncologists in Europe
Efficacy and Safety of Anti-TNF-alpha Biosimilars Comparable to Reference Drugs in RA and AS
Bevacizumab Biosimilar Could Address Global Barriers to Access
Does a Drug's Mechanism Regulate Retention by Patients With Psoriasis?
New Player in the Biosimilars Game: Aurobindo Pharma
